Biotech Already Up Over +300% During Premarket Hours

By: Tomas Ronolski - AllPennyStocks.com News

Tuesday, August 20, 2024

A pharmaceutical company based out of Vancouver is finding an overwhelming amount of success so far during Tuesday’s premarket hours after the company confirmed its INM-901 as an oral formulation that will be utilized in its development programs for Alzheimer's disease.

Shares of InMed Pharmaceuticals Inc. (Nasdaq:INM) rallied strongly on this morning’s announcement, with traders currently willing to buy shares of this micro cap at $0.6851/share (+362.91% implied open for sellers) at the time of writing. Be sure to watch this stock this morning!

InMed Pharmaceuticals Inc is a Canada based pre-clinical stage biopharmaceutical company. The company is engaged in the research and development of novel, cannabinoid-based therapies combined with drug delivery systems. It is focused on the treatment of diseases including pain and inflammation, dermatology, Orofacial Pain, Glaucoma, ocular, CNS, respiratory, metabolic diseases, and others

Copyright © 2024 AllPennyStocks.com. All rights reserved. Republication or redistribution of AllPennyStocks.com's content is expressly prohibited without the prior written consent of AllPennyStocks.com. AllPennyStocks.com shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.